Vantictumab  (Synonyms: OMP-18R5)

Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma^[1][2][3].

Human IgG2 lambda

Human IgG2 lambda, Isotype Control

Human

FZD1/2/5/7/8^[1][2].

Vantictumab modulates gene expression in tumor cells associated with stem cell and differentiation pathways and down-regulates Wnt pathway genes in the tumor and stroma^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

8324  [NCBI]

O75084

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.16 kDa

1345009-45-1

Liquid

Colorless to light yellow

[Vantictumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 lambda

• 
  Loaded Vantictumab on AHC2 biosensor, can bind Frizzled-8 Protein, Human (HEK293, His, HY-P70915) with an affinity constant of 1.183E-07 M as determined in BLI assay.

• [1]. Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun;38(3):821-830.  [Content Brief]

  [2]. Diamond JR, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Nov;184(1):53-62.  [Content Brief]

  [3]. Smith D C, et al. Abstract B24: Biomarker analysis in the first-in-human phase 1a study for vantictumab (OMP-18R5; anti-Frizzled) demonstrates pharmacodynamic (PD) modulation of the Wnt pathway in patients with advanced solid tumors[J]. Molecular Cancer Therapeutics, 2013, 12(11_Supplement): B24-B24.